Compounded Semaglutide vs Retatrutide
A side-by-side research comparison of Compounded Semaglutide and Retatrutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Compounded Semaglutide | Retatrutide |
|---|---|---|
| Full name | Compounded Semaglutide (503B Pharmacy) | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) |
| Category | Weight Management | Weight Management |
| Status | Compounded medication | Phase 3 Clinical Trial |
| Mechanism | Identical to branded semaglutide - a GLP-1 receptor agonist with a fatty acid chain for albumin binding, providing extended half-life. Reduces appetite, slows gastric emptying, and improves insulin sensitivity. | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. |
| Molecular weight | 4113.58 Da | 5,200 Da (approximate) |
| Half-life | ~7 days | 6 days |
| Bioavailability | ~89% subcutaneous | High (SubQ) |
| Typical dose | 0.25-2.4 mg | 1-2 mg → titrate up to 12 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
Compounded Semaglutide reported benefits
- Significant weight loss (15-20%)
- Appetite suppression
- Improved glycemic control
- Cardiovascular benefits
- Reduced food noise
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Related comparisons
Research and educational reference only. Not medical advice.